NK-based cancer therapies | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

137,359 results for “NK-based cancer therapies”

Trials

View all 101736 →

NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.

120 participants · First posted Jan 25, 2018

CAR-NK Cells (CL-NK-003) in Pancreatic Cancer

9 participants · First posted Feb 23, 2026

CAR-NK Cells (CL-NK-001) in Pancreatic Cancer

30 participants · First posted Feb 10, 2025

Drugs

View all 3516 →

VPS34 inhibitor (Global Cancer Technology/Barrow Neurological Insitute/Neuropore Therapies)

NK cell therapies (Wugen)

PMC-005B based NK-cell therapies (PharmAbcine Inc.)

Organizations

View all 1351 →

OS Therapies

United States

Biorestorative Therapies

United States

EVIDENCE-BASED PRACTICE INSTITUTE, INC.

United States

News

View all 30756 →

Sartorius Stedim Biotech Partners with Nanotein Technologies to Enhance Cell Therapy Manufacturing with NanoSpark® Platform

Exelixis Initiates Phase 1 Trial of XB628, a Novel Bispecific NK Cell Engager for Advanced Solid Tumors

Chimeric Therapeutics Raises $6.6 Million to Advance Novel CAR-T and NK Cell Cancer Therapies

Page 1 of 13736